Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN109 PK Study Under Different Dosing Conditions and Meal Timing
NCT07801326Phase 1Completed
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- May 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MWN109 in type 2 diabetes mellitus (T2DM), obesity and Overweight (2 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoints: Maximum Concentration, Minimum Concentration and 4 more. Started May 2026; status: completed.
02
Drugs
MWN109
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on NCT07801326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801326.